Results 291 to 300 of about 556,889 (346)

Editorial: Health Implications of Dietary Fibers and Bioactive Carbohydrates From Natural Resources

Food Science &Nutrition, Volume 13, Issue 5, May 2025.
Bin Du, Baojun Xu
wiley   +1 more source

Molecular profiles and long-term outcomes of Thai children with hepatic glycogen storage disease in Thailand.

World J Clin Pediatr
Vanduangden J, Ittiwut R, Ittiwut C, Phewplung T, Sanpavat A, Sintusek P, Suphapeetiporn K.   +6 more
europepmc   +1 more source

Gastrointestinal complications of hepatic glycogen storage disease: a national survey questionnaire study in China. [PDF]

Orphanet J Rare Dis
Zhang X, Su Z, Wu J, Zeng H, Jiang X, Wang Y, Shen H, Xie X, Xiao Y, Tang Q, Luo X, Zhong X, Chen H, Lan J, Chen Y, Zeng X, Zhang H, Li Z, Zhang Y, Yang M.   +19 more
europepmc   +1 more source

Genetic Variants and Clinical Features of Patients With Glycogen Storage Disease Type Ib.

JAMA Netw Open
Xia Y, Sun Y, Du T, Sun C, Xu Y, Ge W, Liang L, Wang R, Sun M, Xiao B, Qiu W.   +10 more
europepmc   +1 more source

Dapagliflozin ameliorates Lafora disease phenotype in a zebrafish model.

Biomed Pharmacother
Della Vecchia S, Imbrici P, Liantonio A, Naef V, Damiani D, Licitra R, Bernardi S, Marchese M, Santorelli FM.   +8 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Guidelines for management of glycogen storage disease type I - European Study on Glycogen Storage Disease Type I (ESGSD I)

European Journal of Pediatrics, 2002
Life-expectancy in glycogen storage disease type I (GSD I) has improved considerably. Its relative rarity implies that no metabolic centre has experience of large series of patients and experience with long-term management and follow-up at each centre is limited. There is wide variation in methods of dietary and pharmacological treatment.
Jan Peter Rake Æ Gepke Visser Æ Philippe Labrune James V. Leonard Æ Kurt Ullrich Æ G. Peter A. Smit, ESGSD I. Members ofthe ESGSD I are: Austria (W Endres, D Skladal, Innsbruck), Belgium (E Sokal, Brussels), Czech Republic (J Zeman, Prague), France (P Labrune, Clamart), Germany (P Bu ̈ hrdel, Leipzig, K Ullrich, Hamburg, G Da ̈ ublin, U Wendel, Du ̈ sseldorf), Great Britain (P Lee, JV Leonard, G Mieli-Vergani, London), Hungary (L Szo ̈ nyi, Budapest), Italy (P Gandullia, R Gatti, M di Rocco, Genoa, Melis D, G Andria, Naples), Israel (S Moses, Beersheva), Poland (J Taybert, E Pronicka, Warsaw), The Netherlands (JP Rake, GPA Smit, G Visser, Groningen), Turkey (H O ̈ zen, N Kocak, Ankara)   +41 more
openaire   +5 more sources

Renal Disease in Type I Glycogen Storage Disease

New England Journal of Medicine, 1988
Although kidney enlargement occurs in Type I glycogen storage disease, renal disease has not been considered a major problem. Death from renal failure in three patients known to us prompted a study of renal function in this disorder. Of the 38 patients with Type I glycogen storage disease under our care, the 18 children under 10 years old had normal ...
P. C. Kolbeck, Jon I. Scheinman, Yuan-Tsong Chen, James B. Sidbury, Rosalind A. Coleman   +4 more
openaire   +3 more sources

Pulmonary hypertension in glycogen storage disease type I [PDF]

Journal of Inherited Metabolic Disease, 1996
Glycogen storage disease type I (GSD I) is caused by a deficiency in one of the components of the glucose-6-phosphatase (G-6-Pase) system. Most patients have deficient G-6-Pase activity (GSD Ia) or deficient G-6-Pase translocase activity (GSD Ib). Both of these disorders result in hypoglycaemia, hepatomegaly, lactic acidaemia, hyperlipidaemia and ...
Yuan-Tsong Chen, Priya S. Kishnani, A. R. Bengur   +2 more
openaire   +2 more sources